SG11202003635TA - Crystalline salts of a b-raf kinase inhibitor - Google Patents
Crystalline salts of a b-raf kinase inhibitorInfo
- Publication number
- SG11202003635TA SG11202003635TA SG11202003635TA SG11202003635TA SG11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitor
- raf kinase
- crystalline salts
- crystalline
- salts
- Prior art date
Links
- 229940102297 B-raf kinase inhibitor Drugs 0.000 title 1
- 239000002774 b raf kinase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577313P | 2017-10-26 | 2017-10-26 | |
| PCT/US2018/057792 WO2019084459A1 (fr) | 2017-10-26 | 2018-10-26 | Sels et formes cristallines d'inhibiteur de la kinase b-raf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003635TA true SG11202003635TA (en) | 2020-05-28 |
Family
ID=64277870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003635TA SG11202003635TA (en) | 2017-10-26 | 2018-10-26 | Crystalline salts of a b-raf kinase inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11306086B2 (fr) |
| EP (2) | EP3700530B1 (fr) |
| JP (2) | JP7230041B2 (fr) |
| KR (1) | KR20200088345A (fr) |
| CN (2) | CN111818924B (fr) |
| AU (2) | AU2018355528B2 (fr) |
| BR (1) | BR112020008248A2 (fr) |
| CA (1) | CA3080324A1 (fr) |
| ES (1) | ES2947411T3 (fr) |
| IL (1) | IL274027B2 (fr) |
| MX (1) | MX2020004148A (fr) |
| PH (1) | PH12020550485A1 (fr) |
| SG (1) | SG11202003635TA (fr) |
| WO (1) | WO2019084459A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020008248A2 (pt) | 2017-10-26 | 2020-10-20 | Xynomic Pharmaceuticals, Inc. | sais cristalinos de um inibidor da quinase b-raf |
| JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
| JP2007511596A (ja) * | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | 癌の治療において有用なピロロピリミジン化合物 |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| EP1893612B1 (fr) | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Derives de pyrrolo [2, 3-b]pyridine utilises comme inhibiteurs de proteines kinases |
| WO2007123892A2 (fr) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Inhibiteurs raf et leurs utilisations |
| EP1914234A1 (fr) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases |
| WO2010042337A1 (fr) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de 6-azaindole aminopyrimidine ayant une activité inhibitrice de nik |
| NZ597833A (en) * | 2009-09-28 | 2014-01-31 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| JP6263469B2 (ja) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
| CN116271056A (zh) | 2015-04-16 | 2023-06-23 | 日东电工株式会社 | 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物 |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| BR112020008248A2 (pt) | 2017-10-26 | 2020-10-20 | Xynomic Pharmaceuticals, Inc. | sais cristalinos de um inibidor da quinase b-raf |
-
2018
- 2018-10-26 BR BR112020008248-1A patent/BR112020008248A2/pt unknown
- 2018-10-26 CN CN201880081003.9A patent/CN111818924B/zh active Active
- 2018-10-26 KR KR1020207014962A patent/KR20200088345A/ko not_active Application Discontinuation
- 2018-10-26 CA CA3080324A patent/CA3080324A1/fr active Pending
- 2018-10-26 IL IL274027A patent/IL274027B2/en unknown
- 2018-10-26 EP EP18801183.7A patent/EP3700530B1/fr active Active
- 2018-10-26 JP JP2020543248A patent/JP7230041B2/ja active Active
- 2018-10-26 US US16/759,187 patent/US11306086B2/en active Active
- 2018-10-26 WO PCT/US2018/057792 patent/WO2019084459A1/fr unknown
- 2018-10-26 AU AU2018355528A patent/AU2018355528B2/en active Active
- 2018-10-26 MX MX2020004148A patent/MX2020004148A/es unknown
- 2018-10-26 ES ES18801183T patent/ES2947411T3/es active Active
- 2018-10-26 SG SG11202003635TA patent/SG11202003635TA/en unknown
- 2018-10-26 CN CN202310913355.9A patent/CN116942672A/zh active Pending
- 2018-10-26 EP EP23167989.5A patent/EP4245758A3/fr active Pending
-
2020
- 2020-04-24 PH PH12020550485A patent/PH12020550485A1/en unknown
-
2022
- 2022-02-17 AU AU2022201044A patent/AU2022201044B2/en active Active
- 2022-03-11 US US17/692,695 patent/US11753409B2/en active Active
-
2023
- 2023-02-15 JP JP2023021816A patent/JP2023062074A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL274027B1 (en) | 2023-08-01 |
| EP3700530A1 (fr) | 2020-09-02 |
| RU2020116763A (ru) | 2021-11-26 |
| CN116942672A (zh) | 2023-10-27 |
| US11306086B2 (en) | 2022-04-19 |
| AU2022201044B2 (en) | 2023-07-13 |
| CA3080324A1 (fr) | 2019-05-02 |
| AU2018355528A1 (en) | 2020-05-07 |
| WO2019084459A1 (fr) | 2019-05-02 |
| EP4245758A3 (fr) | 2023-12-20 |
| JP2021501199A (ja) | 2021-01-14 |
| US20220204506A1 (en) | 2022-06-30 |
| US11753409B2 (en) | 2023-09-12 |
| JP7230041B2 (ja) | 2023-02-28 |
| ES2947411T3 (es) | 2023-08-08 |
| CN111818924B (zh) | 2023-08-15 |
| AU2022201044A1 (en) | 2022-03-10 |
| KR20200088345A (ko) | 2020-07-22 |
| BR112020008248A2 (pt) | 2020-10-20 |
| EP4245758A2 (fr) | 2023-09-20 |
| IL274027A (en) | 2020-06-30 |
| IL274027B2 (en) | 2023-12-01 |
| AU2018355528B2 (en) | 2021-11-18 |
| JP2023062074A (ja) | 2023-05-02 |
| US20200283433A1 (en) | 2020-09-10 |
| CN111818924A (zh) | 2020-10-23 |
| EP3700530B1 (fr) | 2023-04-19 |
| RU2020116763A3 (fr) | 2022-04-29 |
| MX2020004148A (es) | 2022-09-09 |
| PH12020550485A1 (en) | 2021-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259719A (en) | Tank-binding kinase inhibitor compounds | |
| IL287740A (en) | Maleate salts of b-raf kinase inhibitors, crystalline forms, methods for their preparation and uses | |
| ZA201903093B (en) | Crystalline forms of a magl inhibitor | |
| IL285686B (en) | Crystals in solid form in the presence of an inhibitor | |
| HK1256806A1 (zh) | Pim激酶抑制劑的鹽 | |
| IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL267393A (en) | Crystal forms of a Janus kinase inhibitor | |
| EP3193874A4 (fr) | Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels | |
| IL274027A (en) | B-RAF kinase inhibitor salt crystals | |
| IL272835A (en) | Salts of a compound and crystalline forms thereof | |
| HK1252841A1 (zh) | 噻吩並嘧啶化合物的鹽酸鹽的結晶形式 | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| HK1244006A1 (zh) | Parp抑制劑的結晶形式 | |
| HK1243420A1 (zh) | 新型蛋白酶體抑制劑的結晶形式 |